Japan firm starts Down's therapy test

A Japanese pharmaceutical company said Monday it will begin therapeutic testing of a drug it hopes will slow the decline in quality of life for some people with Down's syndrome.

The firm will trial its "Aricept" donepezil hydrochloride drug, commonly used to treat some of the symptoms of Alzheimer's disease, on people between the ages of 15 and 39 who have Down's syndrome.

Down's is a frequently characterised by diminished mental faculty and , including distinctive facial features.

It is caused by a chromosome defect and is proportionately more common in people born of .

From the mid-teens onwards, roughly six percent of people with Down's syndrome lose physical co-ordination, experience and become more withdrawn, a spokesman for pharmaceutical company Eisai said.

"This testing, if effective, might show that the medication could improve their condition and help improve the quality of their lives," the spokesman said.

It could also ease the burden on their caregivers, he added.

Some of the symptoms experienced by people with Down's syndrome are common to some sufferers of Alzheimer's, for which Aricept has long been prescribed.

The testing will initially involve 10 hospitals across Japan, with dozens of people in the affected age group.

The programme will continue for up to four years, the spokesman said.

The drug is not intended to treat the underlying condition, he said, rather it is hoped it will target some of the symptoms.

Around one in every 830 newborns in the United States has Down's syndrome, according to the National Institutes of Health. This equates to about 250,000 people in the US population, it says.

add to favorites email to friend print save as pdf

Related Stories

Down syndrome trial may hold key to learning

Mar 26, 2013

(Medical Xpress)—An ingredient used for decades in cough syrup, and to treat a variety of conditions, could hold the key to improving memory, language, and learning in people with Down syndrome.

Recommended for you

FDA OKs Cubist antibiotic for serious infections

Dec 20, 2014

The Food and Drug Administration has approved a new medicine to fight complex infections in the abdomen and urinary tract, the fourth antibiotic the agency has approved since May.

Xtoro approved for swimmer's ear

Dec 18, 2014

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

Drug interaction identified for ondansetron, tramadol

Dec 18, 2014

(HealthDay)—In the early postoperative period, ondansetron is associated with increased requirements for tramadol consumption, according to a review and meta-analysis published online Dec. 10 in Anaesthesia.

New system targets germs in donated blood plasma

Dec 17, 2014

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.